Related Experiment Video
Updated: Jul 3, 2025
05:50
Author Spotlight: Point-of-Care Ultrasound for Gastric Content Assessment and Risk Stratification in Perioperative Care
Published on: September 22, 2023
2.8K
Gastric protection in cardiological practice: an Italian survey on the prescriptive attitude
Salvatore E Aragona1, Alberto Margonato2, Salvatore Felis3
1Unit of Surgery, ASST Melegnano Martesana, Melzo Hospital, Melzo, Milan, Italy.
Minerva Cardiology and Angiology
|February 13, 2024
Summary
Italian cardiologists prioritize gastric protection for patients on medications that harm the stomach. A survey revealed that this experience improved prescribing practices, especially regarding proton pump inhibitors (PPIs).
Area of Science:
- Gastroenterology
- Cardiology
- Clinical Pharmacy
Background:
- Gastric protection is crucial for patients using NSAIDs, antiplatelets, and anticoagulants.
- Cardiologists frequently prescribe gastroprotective agents to mitigate medication-induced gastric damage.
Purpose of the Study:
- To investigate the attitudes and practices of Italian cardiologists regarding gastric protection in clinical settings.
- To assess the impact of a survey experience on prescribing habits for gastroprotective agents.
Main Methods:
- A self-administered questionnaire was used to gather data from cardiologists over three months.
- Ninety Italian cardiologists participated in the survey.
Main Results:
- All cardiologists considered gastric protection, with proton pump inhibitors (PPIs) prescribed to 60% of patients.
- The survey experience led to a reassessment of PPI appropriateness, with discontinuation of inappropriate prescriptions.
- A novel triple-action medical device influenced a shift towards more appropriate gastroprotection strategies.
Conclusions:
- Appropriate prescription of gastric protectors is clinically significant.
- Longitudinal survey experience improved prescribing practices for PPIs and encouraged the use of new multi-action gastroprotective devices.
More Related Videos
Related Concept Videos
01:29Gastroesophageal Reflux Disease II: Clinical Features and Management
85
Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
85
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
122
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
122
01:26Peptic Ulcer Disease IV: Management
92
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
92
01:23Gastritis III: Clinical Manifestations and Management
251
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
251
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
486
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
486
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
436
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
436